Nucleus RadioPharma, Inc. announced that it will issue 10,547,047 series A preferred shares at issue price of $5.8879 per share for the gross proceeds of $62,099,958.0313 in funding on September 15, 2023. The shares are convertible and non-redeemable. The shares will be convertible into common shares at a price of $5.8879 per share.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
78.66 USD | -0.98% |
|
+2.89% | +1.78% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.78% | 36.26B | |
+6.26% | 213B | |
+9.15% | 184B | |
+27.89% | 153B | |
+33.77% | 113B | |
+0.80% | 63.66B | |
+18.60% | 53.53B | |
+0.13% | 49.11B | |
-4.37% | 38.73B | |
+21.25% | 31.33B |
- Stock Market
- Equities
- GEHC Stock
- News GE HealthCare Technologies Inc.
- Nucleus RadioPharma, Inc. announced that it expects to receive $62.099958 million in funding